Patents by Inventor Yuichi Kajita

Yuichi Kajita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200392149
    Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: March 7, 2018
    Publication date: December 17, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi MIKAMI, Masaki DAINI, Yuhei MIYANOHANA, Hideo SUZUKI, Kenichiro SHIMOKAWA, Yuichi KAJITA, Masaki OGINO, Tatsuki KOIKE, Kohei TAKEUCHI
  • Publication number: 20200385346
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: December 10, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Masaki OGINO, Kohei TAKEUCHI, Tohru MIYAZAKI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Publication number: 20200385345
    Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: March 7, 2018
    Publication date: December 10, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masaki DAINI, Yuhei MIYANOHANA, Satoshi MIKAMI, Yuichi KAJITA, Masaki OGINO, Tatsuki KOIKE, Kohei TAKEUCHI
  • Patent number: 10741443
    Abstract: According to one embodiment, a method for manufacturing a semiconductor device is disclosed. The method includes forming a co-catalyst layer and catalyst layer above a surface of a semiconductor substrate. The co-catalyst layer and catalyst layer have fcc structure. The fcc structure is formed such that (111) face of the fcc structure is to be oriented parallel to the surface of the semiconductor substrate. The catalyst includes a portion which contacts the co-catalyst layer. The portion has the fcc structure. An exposed surface of the catalyst layer is planarized by oxidation and reduction treatments. A graphene layer is formed on the catalyst layer.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: August 11, 2020
    Assignee: Kioxia Corporation
    Inventors: Masayuki Kitamura, Atsuko Sakata, Makoto Wada, Yuichi Yamazaki, Masayuki Katagiri, Akihiro Kajita, Tadashi Sakai, Naoshi Sakuma, Ichiro Mizushima
  • Publication number: 20200247747
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: January 30, 2020
    Publication date: August 6, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi Hattori, Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike, Yasutaka Hoashi, Norihito Tokunaga, Alexander Martin Pawliczek, Tsuneo Oda, Tohru Miyazaki, Yoshiteru Ito, Kohei Takeuchi, Keisuke Imamura, Takahiro Sugimoto
  • Publication number: 20200207734
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: July 2, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Publication number: 20200207715
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: March 6, 2020
    Publication date: July 2, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei MIYANOHANA, Tatsuki KOIKE, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Patent number: 10584097
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: March 10, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Publication number: 20200017444
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 16, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Patent number: 10428023
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: October 1, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Publication number: 20190259659
    Abstract: According to one embodiment, a method for manufacturing a semiconductor device is disclosed. The method includes forming a co-catalyst layer and catalyst layer above a surface of a semiconductor substrate. The co-catalyst layer and catalyst layer have fcc structure. The fcc structure is formed such that (111) face of the fcc structure is to be oriented parallel to the surface of the semiconductor substrate. The catalyst includes a portion which contacts the co-catalyst layer. The portion has the fcc structure. An exposed surface of the catalyst layer is planarized by oxidation and reduction treatments. A graphene layer is formed on the catalyst layer.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 22, 2019
    Applicant: KABUSHIKI KAISHA TOSHIBA
    Inventors: Masayuki KITAMURA, Atsuko Sakata, Makoto Wada, Yuichi Yamazaki, Masayuki Katagiri, Akihiro Kajita, Tadashi Sakai, Naoshi Sakuma, Ichiro Mizushima
  • Patent number: 10325805
    Abstract: According to one embodiment, a method for manufacturing a semiconductor device is disclosed. The method includes forming a co-catalyst layer and catalyst layer above a surface of a semiconductor substrate. The co-catalyst layer and catalyst layer have fcc structure. The fcc structure is formed such that (111) face of the fcc structure is to be oriented parallel to the surface of the semiconductor substrate. The catalyst includes a portion which contacts the co-catalyst layer. The portion has the fcc structure. An exposed surface of the catalyst layer is planarized by oxidation and reduction treatments. A graphene layer is formed on the catalyst layer.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: June 18, 2019
    Assignee: Kabushiki Kaisha Toshiba
    Inventors: Masayuki Kitamura, Atsuko Sakata, Makoto Wada, Yuichi Yamazaki, Masayuki Katagiri, Akihiro Kajita, Tadashi Sakai, Naoshi Sakuma, Ichiro Mizushima
  • Publication number: 20190040010
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: February 7, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OHYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Patent number: 10112956
    Abstract: An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: October 30, 2018
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuki Koike, Yuichi Kajita, Masato Yoshikawa, Shuhei Ikeda, Eiji Kimura, Tomoaki Hasui, Toshiya Nishi, Hiromi Fukuda
  • Publication number: 20170197983
    Abstract: An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: March 23, 2017
    Publication date: July 13, 2017
    Inventors: Tatsuki KOIKE, Yuichi KAJITA, Masato YOSHIKAWA, Shuhei IKEDA, Eiji KIMURA, Tomoaki HASUI, Toshiya NISHI, Hiromi FUKUDA
  • Patent number: 9643957
    Abstract: An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: May 9, 2017
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuki Koike, Yuichi Kajita, Masato Yoshikawa, Shuhei Ikeda, Hiromi Fukuda
  • Patent number: 9598398
    Abstract: The present invention relates to a compound represented by the formula (I), which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. In the formula (I), each symbol is as defined in the specification.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: March 21, 2017
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuki Koike, Masato Yoshikawa, Haruhi Ando, William John Farnaby, Shuhei Ikeda, Yuichi Kajita, Toshiya Nishi
  • Publication number: 20160264536
    Abstract: The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: October 22, 2014
    Publication date: September 15, 2016
    Inventors: Masaki SETO, Yoshihiro BANNO, Toshihiro IMAEDA, Yuichi KAJITA, Tomoko ASHIZAWA, Masanori KAWASAKI, Shinji NAKAMURA, Satoshi MIKAMI, Izumi NOMURA, Takahiko TANIGUCHI, Shogo MARUI
  • Publication number: 20160024049
    Abstract: The present invention relates to a compound represented by the formula (I), which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. In the formula (I), each symbol is as defined in the specification.
    Type: Application
    Filed: April 3, 2014
    Publication date: January 28, 2016
    Inventors: Tatsuki KOIKE, Masato YOSHIKAWA, Haruhi ANDO, William John FARNABY, Shuhei IKEDA, Yuichi KAJITA, Toshiya NISHI
  • Publication number: 20150315209
    Abstract: An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: December 10, 2013
    Publication date: November 5, 2015
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuki KOIKE, Yuichi KAJITA, Masato YOSHIKAWA, Shuhei IKEDA, Eiji KIMURA, Tomoaki HASUI, Toshiya NISHI, Hiromi FUKUDA